IBA and the University of Pennsylvania partner to advance research of ConformalFLASH® therapy
25 Oktober 2021 - 3:00PM
IBA and the University of Pennsylvania partner to advance research
of ConformalFLASH® therapy
Multi-year research agreement to develop, test
and validate ConformalFLASH® at the Roberts Proton Therapy
Center
Louvain-La-Neuve, Belgium, 25 October
2021 – IBA (Ion Beam Applications S.A., EURONEXT), the
world leader in particle accelerator technology, today announces
that it has signed an agreement with the University of Pennsylvania
(Penn) to advance research in ConformalFLASH®1, a novel method
combining ultra-high dose rate FLASH radiotherapy and the unique
Bragg Peak properties of protons.
The agreement is another successful milestone in
the long-term collaboration between IBA and Penn. FLASH Therapy has
the potential to deliver a paradigm shift in radiation therapy and
cancer treatment, as demonstrated by a growing body of preclinical
evidence2.
ConformalFLASH® is a unique technology that
brings together FLASH irradiation, which offers high doses of
radiotherapy with high precision, with the Proton Bragg Peak, to
optimize and accelerate the radiotherapy process. The two
organizations will use this latest initiative, which builds on a
long-standing collaboration, to develop a science-based approach to
bringing ConformalFLASH® to patients in the clinic.
Olivier Legrain, Chief Executive Officer
of IBA, commented: “This agreement is yet another example
of the strength of the IBA community and the benefits that
partnerships between the company and its clients have, with a joint
goal to make proton therapy better. IBA is fully committed to
developing the future of proton therapy for as many patients as
possible, by building on technologies such as ConformalFLASH®.”
“Our team is constantly striving to provide the
latest and most innovative tools and resources, and we hope through
this research to learn more about how this technology may help
provide treatment more quickly and effectively,” said James
M. Metz, MD, Henry K. Pancoast Professor of Radiation Oncology and
Chair of the Department of Radiation Oncology at the Perelman
School of Medicine at the University of Pennsylvania.
Penn and IBA announced this partnership
during a Conference at ASTRO on Sunday 24th October
2021.
*** END ***
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 1,500 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com.
CONTACTSIBA
Aymeric HarmantProton Therapy Marketing Global
Director+32 10 475 890global.marketing@iba-group.com
Olivier
Lechien
Corporate Communication
Director
+32 10 475
890
communication@iba-group.com
For media and investor enquiries: Consilium
Strategic Communications Amber Fennell, Angela Gray, Lucy
Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com
1 ConformalFLAsH® is a registered brand of IBA’s Proton FLASH
irradiation solution currently under research and development
phase.
2 Diffenderfer, Koumenis, Metz et al. Design, Implementation,
and in Vivo Validation of a Novel Proton FLASH Radiation Therapy
System, Int J Radiation Oncol Biol Phys, 2020Kim et al. Comparison
of FLASH Proton Entrance and the Spread-Out Bragg Peak Dose Regions
in the Sparing of Mouse Intestinal Crypts and in a Pancreatic Tumor
Model, Cancers, 2021
- 2110125-IBA_PENN-Flash-agreement-ENG
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Apr 2023 bis Apr 2024